Publications

Export 1318 results:
Sort by: Author Title [ Type  (Desc)] Year
Journal Article
Wong, D. C. J., R. Schlechter, A. Vannozzi, J. Holl, I. Hmmam, J. Bogs, G. B. Tornielli, S. D. Castellarin, and J. T. Matus, "A systems-oriented analysis of the grapevine R2R3-MYB transcription factor family uncovers new insights into the regulation of stilbene accumulation", DNA Research, vol. 23, issue 5, pp. 451-466, 2016.
Zhang, B., K. Khanoyan, H. Hatamkhani, H. Tong, K. Hu, S. Fallahi, M. Abdul-Latif, K. Vakilian, I. Fujimori, and A. Brewster, "A 28 Gb/s Multistandard Serial Link Transceiver for Backplane Applications in 28 nm CMOS", in Solid-State Circuits, IEEE Journal of, vol. 50, no. no.12: IEEE, pp. pp–3089, 2015. Abstract
n/a
Kocaman, N., T. Ali, L. P. Rao, U. Singh, M. Abdul-Latif, Y. Liu, A. A. Hafez, H. Park, A. Vasani, Z. Huang, et al., "A 3.8 mW/Gbps Quad-Channel 8.5–13 Gbps Serial Link With a 5 Tap DFE and a 4 Tap Transmit FFE in 28 nm CMOS", IEEE Journal of Solid-State Circuits, vol. 51, no. 4: IEEE, pp. 881–892, 2016. Abstract
n/a
Torner, H., D. Janowski, N. Ghanem, D. Salilew-Wondim, H. Alm, W. Tomek, T. Viergutz, and D. Tesfaye, "357 MOLECULAR AND SUBCELLULAR CHARACTERIZATION OF BOVINE OOCYTES AND THEIR SURROUNDING FOLLICULAR CELLS IN SUBJECT TO THEIR DEVELOPMENTAL COMPETENCE", Reproduction, Fertility and Development, vol. 22, issue 1: CSIRO, pp. 335-335, 2009. Abstract
n/a
Abdalla, H. M., A. Hemeida, A. Rashekh, H. Vansompel, A. Arkkio, and P. Sergeant, "A 3D Dynamic Lumped Parameter Thermal Network of Air-Cooled YASA Axial Flux Permanent Magnet Synchronous Machine", Energies, vol. 11, no. 4: MDPI AG, pp. 774, 2018. Abstract
n/a
B.Osman, R., A. V. J. der Veen, D. Huiberts, D. Wismeijer, and N. Alharbi, "3D-printing zirconia implants; a dream or a reality? An in-vitrro study evaluating the dimensional accuracy, surface topography and mechanical properties of printed zirconia implant and discs", Journal of the Mechanical Behavior of Biomedical Materials , vol. 75, pp. 521-528, 2017.
Oing, C., I. Verem, W. Y. Mansour, C. Bokemeyer, S. Dyshlovoy, and F. Honecker, "5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells.", International journal of molecular sciences, vol. 20, issue 1, pp. 21-32, 2018 Dec 21, 2019. Abstract

Despite high cure rates, about 20% of patients with advanced germ cell tumors (GCTs) fail cisplatin-based chemotherapy. High levels of DNA methylation have been identified in GCTs and linked to cisplatin resistance. Here, we examined the effects of DNA hypomethylating 5-azacitidine (5-aza) on two embryonal carcinoma cell lines (NCCIT, 2102Ep) and their cisplatin-resistant isogenic derivatives. Effects on cell viability and cisplatin sensitivity were assessed by the trypan blue exclusion method. Western blotting was used to examine induction of apoptosis 5-aza and results were validated by flow cytometry. Single agent treatment with 5-aza strongly impacted viability and induced apoptosis at low nanomolar concentrations, both in cisplatin-sensitive and -resistant cell lines. 5-aza exerted an immediate apoptotic response, followed by a prolonged inhibitory effect on cell viability and cell-cycle progression. Sequential treatment with 5-aza and cisplatin reduced cellular survival of the cisplatin-resistant sublines already at nanomolar concentrations, suggesting a partial restoration of cisplatin sensitivity by the compound. 5-aza demonstrated anti-tumor activity as a single agent at low nanomolar concentrations in GCT cells, irrespective of cisplatin-sensitivity. 5-aza may also have the potential at least to partially restore cisplatin-sensitivity in non-seminoma cells, supporting the hypothesis that combining DNA demethylating agents with cisplatin-based chemotherapy may be a valid therapeutic approach in patients with refractory GCTs.

Sakr, O. G., R. M. García-García, M. Arias-Álvarez, P. L. Lorenzo, P. Millán, B. Velasco, P. G. Rebollar, I. Badiola, A. Pérez de Rozas, and D. Menoyo, 9 de Febrero de 2012, , Submitted. Abstract
n/a
Nour-Eldin, N. - E. A., S. Exner, M. Al-Subhi, N. N. N. Naguib, B. Kaltenbach, A. Roman, and T. J. Vogl, "Ablation therapy of non-colorectal cancer lung metastases: retrospective analysis of tumour response post-laser-induced interstitial thermotherapy (LITT), radiofrequency ablation (RFA) and microwave ablation (MWA).", International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, vol. 33, issue 7, pp. 820-829, 2017 11. Abstract

PURPOSE: To retrospectively compare the local tumour response and survival rates in patients with non-colorectal cancer lung metastases post-ablation therapy using laser-induced thermotherapy (LITT), radiofrequency ablation (RFA) and microwave ablation (MWA).

MATERIAL AND METHODS: Retrospective analysis of 175 computed tomography (CT)-guided ablation sessions performed on 109 patients (43 males and 66 females, mean age: 56.6 years). Seventeen patients with 22 lesions underwent LITT treatment (tumour size: 1.2-4.8 cm), 29 patients with 49 lesions underwent RFA (tumour size: 0.8-4.5 cm) and 63 patients with 104 lesions underwent MWA treatment (tumour size: 0.6-5 cm). CT scans were performed 24-h post-therapy and on follow-up at 3, 6, 12, 18 and 24 months.

RESULTS: The overall-survival rates at 1-, 2-, 3- and 4-year were 93.8, 56.3, 50.0 and 31.3% for patients treated with LITT; 81.5, 50.0, 45.5 and 24.2% for patients treated with RFA and 97.6, 79.9, 62.3 and 45.4% for patients treated with MWA, respectively. The mean survival time was 34.14 months for MWA, 34.79 months for RFA and 35.32 months for LITT. In paired comparison, a significant difference could be detected between MWA versus RFA (p = 0.032). The progression-free survival showed a median of 23.49 ± 0.62 months for MWA,19.88 ± 2.17 months for LITT and 16.66 ± 0.66 months for RFA (p = 0.048). The lowest recurrence rate was detected in lesions ablated with MWA (7.7%; 8 of 104 lesions) followed by RFA (20.4%; 10 of 49 lesions) and LITT (27.3%; 6 of 22 lesions) p value of 0.012. Pneumothorax was detected in 22.16% of MWA ablations, 22.73% of LITT ablations and 14.23% of RFA ablations.

CONCLUSION: LITT, RFA and MWA may provide an effective therapeutic option for non-colorectal cancer lung metastases with an advantage for MWA regarding local tumour control and progression-free survival rate.

Rivera, S., C. Vens, P. Maingon, A. S. Govaerts, E. Shash, D. Lacombe, W. Grant, and V. Grégoire, "Abstract C220: Combining novel targeted therapies and radiotherapy: A challenge to overcome.", Molecular Cancer Therapeutics, vol. 12, no. 11 Supplement: AACR, pp. C220–C220, 2013. Abstract
n/a
Mahmoud, M., D. M. Stuart, Z. Poulos, A. D. Lascorz, P. Judd, S. Sharify, M. Nikolić, K. Siu, I. E. Vivancos, J. Albericio, et al., "Accelerating Image-Sensor-Based Deep Learning Applications", IEEE Micro, vol. 39, no. 5, pp. 26-35, Sep., 2019. Abstract
n/a
Mostafa, M. A. M., J. Vlasák, and F. Sehnal, "Activities of modified Cry3A‐type toxins on the red flour beetle, Tribolium castaneum (Herbst)", Journal of Applied Entomology, vol. 137, issue 9: Wiley Online Library, pp. 684-692, 2013. Abstract
n/a
Siristatidis, C., K. Dafopoulos, W. El-Khayat, G. Salamalekis, G. Anifandis, T. Vrantza, M. Elsadek, and N. Papantoniou, "Administration of prednisolone and low molecular weight heparin in patients with repeated implantation failures: a cohort study.", Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, vol. 34, issue 2, pp. 136-139, 2018 Feb. Abstract

Conflicting results exist for low molecular weight heparin (LMWH) and prednisolone when tested as separate adjuncts for the improvement of the clinical outcomes in patients with repeated implantation failures (RIF) undergoing IVF/ICSI treatment. Through a cohort study, we evaluated the combined effect of both drugs on pregnancy parameters in 115 women with RIF. Clinical pregnancy rate was the primary end point while the sample size was calculated through the results of a pilot study. Clinical and IVF cycle characteristics were also compared between the groups. Baseline and cycle characteristics were comparable between groups. Biochemical and clinical pregnancy rates were similar in both groups [23/57 (40.4%) vs. 14/58 (24.1%), and 17/57 (29.8%) vs. 11/58 (19%), p = .063, and .175, respectively]. Similarly, miscarriage rates were comparable between the groups (35.7% vs. 34.8%), as well as live birth rates [15/57 (26.3%) vs. 9/58 (15.5%), p = .154]. In conclusion, the administration of LMWH with prednizolone in subfertile women with RIF seems not to improve clinical pregnancy rates, but a full-scaled RCT would definitely be more accurate.

Sonousi, A., J. C. K. Quirke, P. Waduge, T. Janusic, M. Gysin, K. Haldimann, S. Xu, S. N. Hobbie, S. - H. Sha, J. Schacht, et al., "An Advanced Apralog with Increased in vitro and in vivo Activity toward Gram-negative Pathogens and Reduced ex vivo Cochleotoxicity", ChemMedChem, vol. 16, issue 2: John Wiley & Sons, Ltd, pp. 335 - 339, 2021. AbstractWebsite

Abstract We describe the convergent synthesis of a 5-O-?-D-ribofuranosyl-based apramycin derivative (apralog) that displays significantly improved antibacterial activity over the parent apramycin against wild-type ESKAPE pathogens. In addition, the new apralog retains excellent antibacterial activity in the presence of the only aminoglycoside modifying enzyme (AAC(3)-IV) acting on the parent, without incurring susceptibility to the APH(3?) mechanism that disables other 5-O-?-D-ribofuranosyl 2-deoxystreptamine type aminoglycosides by phosphorylation at the ribose 5-position. Consistent with this antibacterial activity, the new apralog has excellent 30?nM activity (IC50) for the inhibition of protein synthesis by the bacterial ribosome in a cell-free translation assay, while retaining the excellent across-the-board selectivity of the parent for inhibition of bacterial over eukaryotic ribosomes. Overall, these characteristics translate into excellent in?vivo efficacy against E. coli in a mouse thigh infection model and reduced ototoxicity vis à vis the parent in mouse cochlear explants.

Vanacker, H., O. Bally, L. Kassem, and T. Bachelot, "Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015", Bulletin du Cancer, vol. 102, issue 6, pp. 47-52, 2015.
Vanacker, H., O. Bally, L. Kassem, O. Tredan, P. Heudel, and T. Bachelot, Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015, , vol. 102, issue 6 Suppl 1, pp. S47 - 52, 2015. Abstract
n/a
Lazarus, J. V., H. E. Mark, Q. M. Anstee, J. P. Arab, R. L. Batterham, L. Castera, H. Cortez-Pinto, J. Crespo, K. Cusi, A. M. Dirac, et al., "Advancing the global public health agenda for NAFLD: a consensus statement.", Nature reviews. Gastroenterology & hepatology, vol. 19, issue 1, pp. 60-78, 2022. Abstract

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics - from epidemiology, awareness, care and treatment to public health policies and leadership - that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD.

Rao, J., S. Ashraf, W. Tan, A. T. van der Ven, H. Y. Gee, D. A. Braun, K. Fehér, S. P. George, A. Esmaeilniakooshkghazi, W. - I. Choi, et al., "Advillin acts upstream of phospholipase C ϵ1 in steroid-resistant nephrotic syndrome.", The Journal of clinical investigation, 2017 Oct 23. Abstract

Steroid-resistant nephrotic syndrome (SRNS) is a frequent cause of chronic kidney disease. Here, we identified recessive mutations in the gene encoding the actin-binding protein advillin (AVIL) in 3 unrelated families with SRNS. While all AVIL mutations resulted in a marked loss of its actin-bundling ability, truncation of AVIL also disrupted colocalization with F-actin, thereby leading to impaired actin binding and severing. Additionally, AVIL colocalized and interacted with the phospholipase enzyme PLCE1 and with the ARP2/3 actin-modulating complex. Knockdown of AVIL in human podocytes reduced actin stress fibers at the cell periphery, prevented recruitment of PLCE1 to the ARP3-rich lamellipodia, blocked EGF-induced generation of diacylglycerol (DAG) by PLCE1, and attenuated the podocyte migration rate (PMR). These effects were reversed by overexpression of WT AVIL but not by overexpression of any of the 3 patient-derived AVIL mutants. The PMR was increased by overexpression of WT Avil or PLCE1, or by EGF stimulation; however, this increased PMR was ameliorated by inhibition of the ARP2/3 complex, indicating that ARP-dependent lamellipodia formation occurs downstream of AVIL and PLCE1 function. Together, these results delineate a comprehensive pathogenic axis of SRNS that integrates loss of AVIL function with alterations in the action of PLCE1, an established SRNS protein.

Griswold, M. G., N. Fullman, C. Hawley, N. Arian, S. R. M. Zimsen, H. D. Tymeson, V. Venkateswaran, A. D. Tapp, M. H. Forouzanfar, and J. S. Salama, "Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016", The Lancet, vol. 392, issue 10152: Elsevier, pp. 1015-1035, 2018. Abstract
n/a
Agarwal, R. P., S. R. Grace, D. O'Regan, S. Albeverio, S. Kuzhel, L. Nizhnik, M. O. Androwuk, M. GS, A. A. Val, and A. A. Vict, "Alfavitnyj pokaΩçyk 59-ho tomu „Ukra] ns\koho matematyçnoho Ωurnalu”", differential equations, vol. 3, pp. 291, Submitted. Abstract
n/a
Elmonem, M. A., K. Veys, F. O. Arcolino, M. van Dyck, M. C. Benedetti, F. Diomedi-Camassei, G. De Hertogh, L. P. van den Heuvel, M. Renard, and E. Levtchenko, "Allogeneic HSCT transfers wild type cystinosin to non-hematological epithelial cells in cystinosis: first human report.", American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2018 Jul 21. Abstract25-_hsct_in_cystinosis.pdf

Cystinosis is an autosomal recessive lysosomal storage disorder characterized by the defective transport of the amino acid cystine out of the lysosome due to a deficiency of cystinosin, the lysosomal cystine transporter. Patients suffer from lysosomal cystine accumulation in various tissues, leading to cellular stress and damage, particularly in the kidney, cornea, and other extra-renal tissues. Cysteamine, a cystine-depleting agent, improves survival and delays the progression of disease, but it does not prevent the development of either renal failure or extra-renal complications. Furthermore, the drug has severe adverse effects that significantly reduce patient compliance. Allogeneic HSCT is currently established as a therapeutic option for many inborn errors of metabolism, where the main pathologic driving factor is an enzyme deficiency. Recent studies in the cystinosis mouse-model suggested that hematopoietic stem cell transplantation (HSCT) could be a curative treatment alternative to cysteamine therapy. We treated a 16-year-old male suffering from infantile cystinosis and side effects of cysteamine therapy with HSCT. We were able to demonstrate successful transfer of the wild type cystinosin protein and CTNS mRNA to non-hematological epithelial cells in the recipient, as well as a decrease in the tissue cystine-crystal burden. This is the first report of allogeneic HSCT in a patient with cystinosis, the prototype of lysosomal membrane-transporter disorders. This article is protected by copyright. All rights reserved.

Jordaens, L., V. Van Hoeck, I. Pintelon, S. Thys, P. E. J. Bols, W. F. A. Marei, and J. Leroy, "Altered embryotrophic capacities of the bovine oviduct under elevated free fatty acid conditions: an in vitro embryo--oviduct co-culture model", Reprod Fertil Dev, 2020/02/11, vol. 32, no. 6, pp. 553-563, Mar, 2020. AbstractWebsite

Maternal metabolic stress conditions are of growing importance in both human and dairy cattle settings as they can have significant repercussions on fertility. Upregulated lipolysis is a common trait associated with metabolic disorders and results in systemically elevated concentrations of non-esterified fatty acids (NEFAs). The effects of high NEFA concentrations on the follicular environment, oocyte and embryo development is well documented. However, knowledge on the effects of NEFAs within the oviduct, representing the initial embryonic growth environment, is currently lacking. Therefore, the experiments outlined here were designed to obtain fundamental insights into both the direct and indirect interactions between NEFAs, bovine oviductal cells and developing zygotes. Hence, zygotes were co-cultured with NEFA-pre-exposed bovine oviductal cells or subjected to simultaneous NEFA exposure during the co-culture period. The outcome parameters assessed were embryo development with cleavage (48h post insemination (pi)), morula (120-126h pi) and blastocyst (192h pi) rates, as well as morula intracellular lipid content and blastocyst quality using Bodipy and differential staining respectively. Our data suggest a direct embryotoxicity of NEFAs as well as impaired embryo development through a reduced oviductal ability to support and protect early embryo development.

Gaggiano, C., D. Rigante, J. Hernández-Rodríguez, A. Vitale, M. Tarsia, A. Soriano, G. Lopalco, F. Iannone, M. Abdel Jaber, R. Giacomelli, et al., "Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network", Therapeutic Advances in Musculoskeletal DiseaseTherapeutic Advances in Musculoskeletal Disease, vol. 13: SAGE Publications, pp. 1759720X211037178, 2021. AbstractWebsite

Background:This study aims at describing the therapeutic outcome of patients carrying the R92Q variant in the TNFRSF1A gene treated with anakinra (ANA) or canakinumab (CAN) and identifying any factors predictive of complete response to IL-1 inhibition.Methods:Clinical data of patients treated with ANA or CAN for recurrent inflammatory attacks due to the presence of the R92Q variant were retrospectively collected and analysed.Results:Data about 20 treatment courses with IL-1 inhibitors (16 with ANA and 4 with CAN) from 19 patients were collected. Mean age at disease onset was 20.2?±?14.8 years. In 5 cases (26%) the R92Q variant was found in a family member affected by recurrent fever. The therapeutic response was complete in 13(68%) and partial in 2 patients (11%); treatment failure was observed in 4 cases (21%). Median AIDAI decreased from 10 (interquartile range [IQR]?=?28) to 0 (IQR?=?1) at the 12-month follow-up visit (p?<?0.001). Mean ESR and median CRP dropped respectively from 40.8?±?24.8 to 9.1?±?4.5 mm/h (p?<?0.001) and from 3.0 (IQR?=?1.9) to 0.3 (IQR?=?0.3) mg/dl (p?<?0.001) after 12 months of treatment. A steroid-sparing effect was observed from the third month of treatment (p?<?0.01). Thirteen patients (65%) were still on treatment at the last follow-up visit (median duration of treatment 17 (IQR?=?38) months). The presence of R92Q mutation in a symptomatic relative (p?=?0.022), the relapsing remitting disease course (p?<?0.001) and the presence of migratory erythematous skin rashes during fever attacks (p?=?0.005) were associated with complete efficacy of IL-1 inhibitors.Conclusions:R92Q patients showed a favourable response to ANA and CAN, particularly when the mutation segregated in a family member and when a relapsing-remitting disease course or TNF-α receptor-associated periodic syndrome (TRAPS) typical skin rash were observed. In the subgroup of patients not taking advantage of IL-1 blockage different molecular mechanisms underlying the autoinflammatory picture are likely to exist.

Gaggiano, C., D. Rigante, J. Hernández-Rodríguez, A. Vitale, M. Tarsia, A. Soriano, G. Lopalco, F. Iannone, M. Abdel Jaber, R. Giacomelli, et al., "Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network", Therapeutic Advances in Musculoskeletal Disease, vol. 13: SAGE Publications Ltd, 2021. AbstractWebsite
n/a
Koornneef, M., L. Bentsink, S. E. D. El-Assal, J. J. B. Keurentjes, D. Vreugdenhil, and C. Alonso-Blanco, The analysis of natural variation in Arabidopsis and the cloning of QTLs of ecologically and agronomically important genes, , 2004. Abstract
n/a
Tourism